{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:22:30Z","timestamp":1786119750253,"version":"build-2736575974"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:00:00Z","timestamp":1764201600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>\n                      Sarcoidosis is a multisystemic granulomatous disease with highly variable manifestations and outcomes, making clinical management challenging. This study evaluated the prognostic value of biomarkers derived from\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG PET\/CT imaging.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods:<\/jats:title>\n                    <jats:p>\n                      From an institutional registry, 75 sarcoidosis patients with a\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG PET\/CT scan performed at the time of initial diagnosis were selected. A composite progression endpoint was defined, comprising either a decrease in FVC&gt;5%, in DLCO&gt;10%, a worsening of radiologic findings, increasing clinical symptoms, or death. Disease progression was assessed by onset at 1 year, 2 years, and overall. The MV of thoracic and extrathoracic lesions attributed to sarcoidosis was calculated, using a SUV threshold of 2.5. SUV\n                      <jats:sub>max<\/jats:sub>\n                      was also determined for these regions.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Of 75 patients, 45 patients met the progression criteria while 30 patients remained in remission. Baseline MV\n                      <jats:sub>thoracic<\/jats:sub>\n                      (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.002) and MV\n                      <jats:sub>whole-body<\/jats:sub>\n                      (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001) were higher in patients subsequently showing progression, while no significant differences were observed in whole-body or organ-specific SUV\n                      <jats:sub>max<\/jats:sub>\n                      . The optimum threshold of MV\n                      <jats:sub>thoracic<\/jats:sub>\n                      for prognosis of overall disease progression was determined at 150\u00a0cm\n                      <jats:sup>3<\/jats:sup>\n                      , yielding an OR of 1.9 in the univariate analysis (MV\n                      <jats:sub>thoracic<\/jats:sub>\n                      &gt;150 vs &lt;150\u00a0cm\n                      <jats:sup>3<\/jats:sup>\n                      ; 95% CI: 1.00\u20133.49;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.049). For MV\n                      <jats:sub>whole-body<\/jats:sub>\n                      , the optimal cutoff value was also determined at 150\u00a0cm\n                      <jats:sup>3<\/jats:sup>\n                      , with an OR of 2.06 (MV\n                      <jats:sub>whole body<\/jats:sub>\n                      &gt;150vs &lt;150\u00a0cm\n                      <jats:sup>3<\/jats:sup>\n                      ; 95% CI: 1.08\u20133.95;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.029). Neither total nor organ-specific SUVmax had significant associations with progression outcomes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>\n                      Volume-based biomarkers derived from\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG PET\/CT were associated with disease progression in pulmonary sarcoidosis, whereas SUV\n                      <jats:sub>max<\/jats:sub>\n                      showed no prognostic implications.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/rlu.0000000000006212","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T19:00:33Z","timestamp":1767812433000},"page":"91-98","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Prognostic Implications of Volume-based Quantitative 18F-FDG PET\/CT Biomarkers in Pulmonary Sarcoidosis"],"prefix":"10.1097","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-2589-2248","authenticated-orcid":false,"given":"Guangyu","family":"Shao","sequence":"first","affiliation":[{"name":"Department of Internal Medicine 4 - Pulmonology, Kepler University Hospital, Johannes Kepler University, Linz, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Kaiser","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine 4 - Pulmonology, Kepler University Hospital, Johannes Kepler University, Linz, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Gabriel","sequence":"additional","affiliation":[{"name":"Institute of Nuclear Medicine and Endocrinology, Kepler University Hospital, Linz, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3365-3449","authenticated-orcid":false,"given":"Bernd","family":"Lamprecht","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine 4 - Pulmonology, Kepler University Hospital, Johannes Kepler University, Linz, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3098-1554","authenticated-orcid":false,"given":"David","family":"Lang","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine 4 - Pulmonology, Kepler University Hospital, Johannes Kepler University, Linz, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,11,27]]},"reference":[{"key":"R1-20260107","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41572-019-0096-x","article-title":"Sarcoidosis","volume":"5","author":"Grunewald","year":"2019","journal-title":"Nat Rev Dis Primer England"},{"key":"R2-20260107","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1056\/NEJMra2101555","article-title":"Challenges of sarcoidosis and its management","volume":"385","author":"Drent","year":"2021","journal-title":"N Engl J Med United States"},{"key":"R3-20260107","doi-asserted-by":"crossref","first-page":"2004079","DOI":"10.1183\/13993003.04079-2020","article-title":"ERS clinical practice guidelines on treatment of sarcoidosis","volume":"58","author":"Baughman","year":"2021","journal-title":"Eur Respir J England"},{"key":"R4-20260107","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S2213-2600(18)30064-X","article-title":"Pulmonary sarcoidosis","volume":"6","author":"Spagnolo","year":"2018","journal-title":"Lancet Respir Med"},{"key":"R5-20260107","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.3389\/fimmu.2020.01443","article-title":"Biomarkers in the diagnosis and prognosis of sarcoidosis: current use and future prospects","volume":"11","author":"Kraaijvanger","year":"2020","journal-title":"Front Immunol"},{"key":"R6-20260107","first-page":"1551","article-title":"FDG uptake and glucose transporter subtype expressions in experimental tumor and inflammation models","volume":"42","author":"Mochizuki","year":"2001","journal-title":"J Nucl Med"},{"key":"R7-20260107","doi-asserted-by":"crossref","first-page":"890","DOI":"10.3390\/jcm9030890","article-title":"In which patients with sarcoidosis is FDG PET\/CT indicated?","volume":"9","author":"Keijsers","year":"2020","journal-title":"J Clin Med"},{"key":"R8-20260107","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1183\/09031936.00088612","article-title":"Imaging the inflammatory activity of sarcoidosis","volume":"41","author":"Keijsers","year":"2013","journal-title":"Eur Respir J England"},{"key":"R9-20260107","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1164\/rccm.202002-0251ST","article-title":"Diagnosis and detection of sarcoidosis. An official American Thoracic Society clinical practice guideline","volume":"201","author":"Crouser","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"R10-20260107","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s00508-024-02444-z","article-title":"Position paper of the Austrian Society for Rheumatology and the Austrian Society for Pneumology on the diagnosis and treatment of sarcoidosis 2024","volume":"136","author":"Sterniste","year":"2024","journal-title":"Wien Klin Wochenschr Austria"},{"key":"R11-20260107","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1200\/JCO.2016.69.3747","article-title":"Metabolic tumor volume in lymphoma: hype or hope?","volume":"34","author":"Sch\u00f6der","year":"2016","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol United States"},{"key":"R12-20260107","first-page":"120","article-title":"Prognostic value of FDG PET\/CT-based metabolic tumor volumes in metastatic triple negative breast cancer patients","volume":"6","author":"Marinelli","year":"2016","journal-title":"Am J Nucl Med Mol Imaging United States"},{"key":"R13-20260107","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1007\/s00259-017-3753-x","article-title":"Optimal FDG PET\/CT volumetric parameters for risk stratification in patients with locally advanced non-small cell lung cancer: results from the ACRIN 6668\/RTOG 0235 trial","volume":"44","author":"Salavati","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging Germany"},{"key":"R14-20260107","first-page":"884","article-title":"Prognostic value of metabolic tumor volume and total lesion glycolysis in head and neck cancer: a systematic review and meta-analysis","volume":"55","author":"Pak","year":"2014","journal-title":"J Nucl Med Off Publ Soc Nucl Med United States"},{"key":"R15-20260107","doi-asserted-by":"crossref","first-page":"6096","DOI":"10.3390\/cancers13236096","article-title":"First-line pembrolizumab mono- or combination therapy of non-small cell lung cancer: baseline metabolic biomarkers predict outcomes","volume":"13","author":"Lang","year":"2021","journal-title":"Cancers Basel"},{"key":"R18-20260107","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s13139-017-0493-6","article-title":"Current methods to define metabolic tumor volume in positron emission tomography: which one is better?","volume":"52","author":"Im","year":"2018","journal-title":"Nucl Med Mol Imaging"},{"key":"R21-20260107","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1007\/s00330-024-11194-5","article-title":"Meta-analysis of [(18)F]FDG-PET\/CT in pulmonary sarcoidosis","volume":"35","author":"Donnelly","year":"2024","journal-title":"Eur Radiol Germany"},{"key":"R24-20260107","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1183\/09031936.00055213","article-title":"Prediction of relapse after discontinuation of infliximab therapy in severe sarcoidosis","volume":"43","author":"Vorselaars","year":"2014","journal-title":"Eur Respir J England"},{"key":"R25-20260107","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s13550-019-0505-x","article-title":"Quantification of pulmonary disease activity in sarcoidosis measured with (18)F-FDG PET\/CT: SUVmax versus total lung glycolysis","volume":"9","author":"Schimmelpennink","year":"2019","journal-title":"EJNMMI Res"},{"key":"R26-20260107","first-page":"44","article-title":"Volumetric FDG PET analysis of global lung inflammation: new tool for precision medicine in pulmonary sarcoidosis? Sarcoidosis","volume":"35","author":"Adams","year":"2018","journal-title":"Vasc Diffuse Lung Dis"},{"key":"R27-20260107","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"61","author":"von Elm","year":"2008","journal-title":"J Clin Epidemiol"},{"key":"R28-20260107","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1586\/17476348.2014.879827","article-title":"The clinical utility of bronchoalveolar lavage in interstitial lung disease - is it really useful?","volume":"8","author":"Meyer","year":"2014","journal-title":"Expert Rev Respir Med England"},{"key":"R29-20260107","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1164\/rccm.201202-0320ST","article-title":"An official American Thoracic Society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease","volume":"185","author":"Meyer","year":"2012","journal-title":"Am J Respir Crit Care Med United States"},{"key":"R30-20260107","doi-asserted-by":"crossref","first-page":"6701","DOI":"10.3390\/jcm12216701","article-title":"Pulmonary function in pulmonary sarcoidosis","volume":"12","author":"Yao","year":"2023","journal-title":"J Clin Med Switzerland"},{"key":"R31-20260107","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1513\/AnnalsATS.202208-731ED","article-title":"Pulmonary sarcoidosis: beyond restriction and forced vital capacity","volume":"20","author":"Obi","year":"2023","journal-title":"Ann Am Thorac Soc United States"},{"key":"R32-20260107","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1136\/thoraxjnl-2019-214348","article-title":"BTS clinical statement on pulmonary sarcoidosis","volume":"76","author":"Thillai","year":"2021","journal-title":"Thorax England"},{"key":"R34-20260107","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1183\/09031936.93.02020135","article-title":"V\/Q and alveolar gas exchange in pulmonary sarcoidosis","volume":"2","author":"Eklund","year":"1989","journal-title":"Eur Respir J England"},{"key":"R35-20260107","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ijrobp.2003.10.045","article-title":"FDG-PET in radiotherapy treatment planning: Pandora\u2019s box?","volume":"59","author":"Paulino","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys United States"},{"key":"R36-20260107","first-page":"5087","article-title":"Prognostic value of preoperative metabolic tumor volumes on PET-CT in predicting disease-free survival of patients with stage I non-small cell lung cancer","volume":"32","author":"Lin","year":"2012","journal-title":"Anticancer Res Greece"},{"key":"R37-20260107","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1056\/NEJMoa2501443","article-title":"First-line treatment of pulmonary sarcoidosis with prednisone or methotrexate","volume":"393","author":"Kahlmann","year":"2025","journal-title":"N Engl J Med United States"},{"key":"R38-20260107","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1183\/09031936.00138913","article-title":"Relapses of sarcoidosis: what are they and can we predict who will get them?","volume":"43","author":"Baughman","year":"2014","journal-title":"Eur Respir J England"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/RLU.0000000000006212","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T19:00:19Z","timestamp":1786042819000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/RLU.0000000000006212"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,27]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000006212","relation":{},"ISSN":["0363-9762","1536-0229"],"issn-type":[{"value":"0363-9762","type":"print"},{"value":"1536-0229","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,27]]},"assertion":[{"value":"2025-06-21","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-10","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}